Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. - Theroux,P.; Armstrong,PW.; Mahaffey,KW.; Hochman,JS.; Malloy,KJ.; Rollins,S.; Nicolau,JC.; Lavoie,J.; Luong,TM.; Burchenal,J.; Granger,CB. (Eur Heart J, 2005)